argenx SE

Symbol: ARGX

NASDAQ

393.49

USD

Market price today

  • -73.5992

    P/E Ratio

  • 6.0012

    PEG Ratio

  • 21.99B

    MRK Cap

  • 0.00%

    DIV Yield

argenx SE (ARGX) Stock Price & Analysis

Shares Outstanding

59.43M

Gross Profit Margin

0.82%

Operating Profit Margin

-0.35%

Net Profit Margin

-0.24%

Return on Assets

-0.06%

Return on Equity

-0.10%

Return on Capital Employed

-0.11%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.
Full-time employees:843
City:Breda
Address:Willemstraat 5
IPO:2017-05-18
CIK:0001697862

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

General Outlook

In simple terms, argenx SE has 59.431 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.820% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.354%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.241%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.065% return, is a testament to argenx SE's adeptness in optimizing resource deployment. argenx SE's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.096%. Furthermore, the proficiency of argenx SE in capital utilization is underscored by a remarkable -0.105% return on capital employed.

Stock Prices

argenx SE's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $399.87, while its low point bottomed out at $388.11. This variance in figures offers investors a lucid insight into the roller-coaster ride that is argenx SE's stock market.

Liquidity Ratios

Analyzing ARGX liquidity ratios reveals its financial health of the firm. The current ratio of 974.89% gauges short-term asset coverage for liabilities. The quick ratio (869.78%) assesses immediate liquidity, while the cash ratio (484.37%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio974.89%
Quick Ratio869.78%
Cash Ratio484.37%

Profitability Ratios

ARGX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -24.68% underscores its earnings before tax deductions. The effective tax rate stands at 3.10%, revealing its tax efficiency. The net income per EBT, 97.49%, and the EBT per EBIT, 69.69%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -35.41%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-24.68%
Effective Tax Rate3.10%
Net Income per EBT97.49%
EBT per EBIT69.69%
EBIT per Revenue-35.41%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 9.75, it details the span from stock purchase to revenue. The 9 days it takes to settle debts showcases its creditor relations. Meanwhile, a 5 cash conversion cycle and 245.74% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding870
Days of Inventory Outstanding512
Operating Cycle660.56
Days of Payables Outstanding405
Cash Conversion Cycle256
Receivables Turnover2.46
Payables Turnover0.90
Inventory Turnover0.71
Fixed Asset Turnover54.11
Asset Turnover0.27

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -5.63, and free cash flow per share, -6.38, depict cash generation on a per-share basis. The cash per share value, 54.56, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.27, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-5.63
Free Cash Flow per Share-6.38
Cash per Share54.56
Operating Cash Flow Sales Ratio-0.27
Free Cash Flow to Operating Cash Flow Ratio1.13
Cash Flow Coverage Ratio-16.40
Short Term Coverage Ratio-70.61
Capital Expenditure Coverage Ratio-7.48
Dividend Paid and Capex Coverage Ratio-7.48

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.44%, highlights its total liabilities relative to assets. The long-term debt to capitalization, 0.37%, and total debt to capitalization, 0.49%, ratios shed light on its capital structure. An interest coverage of -479.34 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.44%
Long Term Debt to Capitalization0.37%
Total Debt to Capitalization0.49%
Interest Coverage-479.34
Cash Flow to Debt Ratio-16.40
Company Equity Multiplier1.11

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 21.45, provides a glimpse into top-line earnings distributed across each share. Net income per share, -5.16, reflects the portion of profit attributed to each share. The book value per share, 71.67, represents the net asset value distributed per share, while the tangible book value per share, 69.48, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share21.45
Net Income Per Share-5.16
Book Value Per Share71.67
Tangible Book Value Per Share69.48
Shareholders Equity Per Share71.67
Interest Debt Per Share0.37
Capex Per Share-0.77

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 198.56%, indicates top-line expansion, while the gross profit growth, 190.70%, reveals profitability trends. EBIT growth, 40.94%, and operating income growth, 40.94%, offer insights into operational profitability progression. The net income growth, 58.42%, showcases bottom-line expansion, and the EPS growth, 60.46%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth198.56%
Gross Profit Growth190.70%
EBIT Growth40.94%
Operating Income Growth40.94%
Net Income Growth58.42%
EPS Growth60.46%
EPS Diluted Growth60.46%
Weighted Average Shares Growth5.13%
Weighted Average Shares Diluted Growth5.13%
Operating Cash Flow Growth51.28%
Free Cash Flow Growth51.98%
10-Year Revenue Growth per Share9013.37%
5-Year Revenue Growth per Share3040.37%
3-Year Revenue Growth per Share2074.24%
10-Year Operating CF Growth per Share-1280.79%
5-Year Operating CF Growth per Share-329.48%
3-Year Operating CF Growth per Share21.62%
10-Year Net Income Growth per Share-857.40%
5-Year Net Income Growth per Share-143.56%
3-Year Net Income Growth per Share63.97%
10-Year Shareholders Equity Growth per Share3655.65%
5-Year Shareholders Equity Growth per Share318.67%
3-Year Shareholders Equity Growth per Share93.95%
Receivables Growth80.06%
Inventory Growth36.00%
Asset Growth44.93%
Book Value per Share Growth38.53%
Debt Growth60.95%
R&D Expense Growth29.57%
SGA Expenses Growth50.28%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 19,720,054,918.79, captures the company's total value, considering both debt and equity. Income quality, 0.99, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.41, gauges operational efficiency, while the research and development to revenue, 70.09%, highlights investment in innovation. The ratio of intangibles to total assets, 2.76%, indicates the value of non-physical assets, and capex to operating cash flow, 10.42%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value19,720,054,918.79
Income Quality0.99
Sales General and Administrative to Revenue0.41
Research and Development to Revenue70.09%
Intangibles to Total Assets2.76%
Capex to Operating Cash Flow10.42%
Capex to Revenue-3.57%
Capex to Depreciation-39.36%
Stock-Based Compensation to Revenue19.00%
Graham Number91.23
Return on Tangible Assets-6.68%
Graham Net Net57.10
Working Capital3,700,744,000
Tangible Asset Value3,972,279,000
Net Current Asset Value3,678,786,000
Average Receivables388,273,000
Average Payables217,139,000
Average Inventory269,451,500
Days Sales Outstanding149
Days Payables Outstanding761
Days of Inventory On Hand962
ROIC-10.00%
ROE-0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.30, and the price to book ratio, 5.30, reflect the market's valuation relative to the company's book value. The price to sales ratio, 18.06, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -59.57, and price to operating cash flows, -66.23, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.30
Price to Book Ratio5.30
Price to Sales Ratio18.06
Price Cash Flow Ratio-66.23
Price Earnings to Growth Ratio6.00
Enterprise Value Multiple-91.64
Price Fair Value5.30
Price to Operating Cash Flow Ratio-66.23
Price to Free Cash Flows Ratio-59.57
Price to Tangible Book Ratio5.31
Enterprise Value to Sales16.08
Enterprise Value Over EBITDA-89.32
EV to Operating Cash Flow-46.92
Earnings Yield-1.36%
Free Cash Flow Yield-2.13%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of argenx SE (ARGX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -73.599 in 2024.

What is the ticker symbol of argenx SE stock?

The ticker symbol of argenx SE stock is ARGX.

What is company IPO date?

IPO date of argenx SE is 2017-05-18.

What is company current share price?

Current share price is 393.490 USD.

What is stock market cap today?

The market cap of stock today is 21989886843.000.

What is PEG ratio in 2024?

The current 6.001 is 6.001 in 2024.

What is the number of employees in 2024?

In 2024 the company has 843.